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ABSTRACT: The need for high-concentration formulations for
subcutaneous delivery of therapeutic monoclonal antibodies (mAbs)
can present manufacturability challenges for the ﬁnal ultraﬁltration/
diaﬁltration (UF/DF) step. Viscosity levels and the propensity to
aggregate are key considerations for high-concentration formula-
tions. This work presents novel frameworks for deriving a set of
manufacturability indices related to viscosity and thermostability to
rank high-concentration mAb formulation conditions in terms of
their ease of manufacture. This is illustrated by analyzing published
high-throughput biophysical screening data that explores the
inﬂuence of different formulation conditions (pH, ions, and
excipients) on the solution viscosity and product thermostability.
A decision tree classiﬁcation method, CART (Classiﬁcation and
Regression Tree) is used to identify the critical formulation
conditions that inﬂuence the viscosity and thermostability. In this
work, three different multi-criteria data analysis frameworks were
investigated to derive manufacturability indices from analysis of the
stress maps and the process conditions experienced in the ﬁnal UF/
DF step. Polynomial regression techniqueswere used to transform the
experimental data into a set of stress maps that show viscosity and
thermostability as functions of the formulation conditions. A
mathematical ﬁltrate ﬂuxmodel was used to capture the time proﬁles
of protein concentration and ﬂux decay behavior during UF/DF.
Multi-criteria decision-making analysis was used to identify the
optimal formulation conditions that minimize the potential for both
viscosity and aggregation issues during UF/DF.
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Introduction
The dominance of monoclonal antibodies (mAbs) in biopharma-
ceutical pipelines combined with their success in treating chronic
conditions has triggered a shift in their ﬁnal dosage form and
delivery mode to high-concentration formulations. Typical
formulation studies explore the responses of the ﬁnal product to
different formulation conditions but do not typically translate these
to predicting the ease of manufacture. Yet this becomes important
to understand especially with high-concentration formulations that
have the potential to pose manufacturing challenges. Hence this
paper proposes a novel methodology to predict manufacturability
in the ﬁnal ultraﬁltration/diaﬁltration (UF/DF) step of a mAb
process based on biophysical data derived from formulation studies.
Traditionally mAbs have been formulated at low concentrations
(e.g., 20 g/L) for intravenous administration in hospitals (see
Table I). More recently, high-concentration and low-volume
(<1.5 ml) formulations have been developed (e.g., 100 g/L) for
sub-cutaneous delivery that can be self-administered in the home
and thus lower hospital administration costs while enhancing the
ease of administration and hence patient compliance (Harris et al.,
2004; Rao and Gefroh, 2012). Table I provides a list of commercial
mAb-based products with their concentrations and routes of
administration.
High-concentration formulations of mAbs can pose manufactur-
ing and delivery challenges. These can be attributed to the higher
propensity of antibodies to form soluble aggregates and to be more
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viscous at high concentrations given the higher probability for
protein-protein interactions (Arakawa and Timasheff, 1985; Shire,
2009; Shire et al., 2004; Treuheit et al., 2002). For example, it has
been reported that viscosity values above 10 cP were observed with
mAbs at concentrations above 100–150mgmL1 (He et al., 2010a;
Monkos and Turczynski, 1999; Patapoff and Esue, 2009).
On the manufacturing front, biopharmaceutical manufacturers
(He et al., 2011c; Rao and Gefroh, 2012; Shire, 2009) have
commented that high concentration formulations present down-
stream processing challenges, in particular for the ﬁnal ultraﬁltra-
tion/diaﬁltration stage that uses tangential ﬂow ﬁltration (TFF) to
buffer exchange and concentrate the product to meet the ﬁnal
product speciﬁcation. Moreover, Shire et al. (2004) and Rao and
Gefroh (2012) observed that the higher viscosities at higher
concentrations may make recovery of the ﬁnal product from the
UF/DF step more difﬁcult and hence result in excessive product
losses. It may also result in high back-pressures during the UF/DF
process that can affect the system pumps and reduce the ﬂux (Shire
et al., 2004). Therefore, selection of formulation conditions and
excipients that reduce the viscosity and minimize the propensity to
aggregate is not only a priority for formulation studies considering
storage and delivery of high concentration products but also for
attaining feasible manufacturing processes given equipment
limitations. Hence a closer linkage between formulation studies
and manufacturability is needed to successfully realize high
concentration formulations.
Formulation studies typically examine the impact of stress
conditions such as pH, temperature, concentration, ions, and
excipients on protein properties such as viscosity and stability.
Reported strategies to reduce viscosity include control of pH in
relation to the pI (Webb et al., 2002; Winters et al., 1996; Yadav et al.,
2010a) and the addition of excipients including cations and anions
to increase the ionic strength of the formulation (Kanai et al., 2008).
However, designing an appropriate formulation can be complicated
since some formulation strategies to decrease viscosity can also
increase aggregation by lowering the thermostability of the protein
solution (He et al., 2010b). Therefore, the optimal strategy design
would aim to select formulation conditions that minimize viscosity
while maximizing thermostability. A key challenge is considering
how to map the stress responses obtained in formulation studies
onto the manufacturing process. This will enable selection of
formulation strategies that can also help avoid manufacturing
complications when handling high-protein concentrations.
This paper presents a novel concept of manufacturability indices
that can be used as predictors in early stage development to rank
high-concentration mAb formulation conditions in terms of their
ease of manufacture and formulation with respect to minimizing
viscosity and aggregation issues during the ﬁnal UF/DF step. This
work builds on the notion of manufacturability indices ﬁrst proposed
by the authors in Yang et al. (2015) and presents multiple advanced
frameworks for predicting the ease of manufacture. In the present
work, published high-throughput biophysical screening data that
explored the inﬂuence of different formulation conditions (pH, ions,
and excipients) on the solution viscosity and product thermostability
were used for the study. The CARTdecision tree classiﬁcationmethod
was applied to identify the major formulation conditions inﬂuencing
viscosity and thermostability. A polynomial regression method was
applied to transform the experimental data into a set of stress maps
which indicate viscosity and thermostability as functions of the
formulation conditions. A mathematical model from Ho and Zydney
(2000) for the expected ﬂux decay behavior during membrane
ﬁltration was adapted and incorporated to capture the impact of
protein concentration-time proﬁles on manufacturability. The stress
maps are thereby transformed into functions of the formulation
Table I. Commercial antibodies with concentrations and routes of administration adapted from Meyer and Shameem (2012).
Name Trade Name Company Active concentration (g/L) Dose per container (mg) Mode of administration
Adalimumab Humira Abbott Labs (North Chicago, IL) 50 20, 40 SC
Basiliximab Simulect Novartis (Basel, Switzerland) 4 10 IV
Bevacizumab Avastin Genentech (South San Francisco, CA) 25 100, 400 IV
Canakinumab Ilaris Novartis (Basel, Switzerland) 150 150 SC
Certolizumab Cimzia UCB (Brussels, Belgium) 200 100 SC
Pegol
Cetuximab Erbitux Eli Lilly and Co (Indianapolis, IN) 2 100, 200 IV
Denileukin diftitox Ontak Ligand Pharma (San Diego, CA) 0.15 0.3 IV
Denosumab Prolia Amgen (Thousand Oaks, CA) 60 60 SC
Golimumab Simponi Janssen Biotech (Horsham, PA) 100 50 SC
Ibritumomab Zevalin Spectrum Pharmaceuticals (Henderson, NV) 1.6 3.2 IV
Infliximab Remicade Janssen Biotech (Horsham, PA) 10 100 IV
Muromomab Okt3 Janssen Biotech (Horsham, PA) 1 5 IV
Ofatumumab Arzerra GlaxoSmithKline (Seattle, WA) 20 100 IV
Omalizumab Xolair Genentech (South San Francisco, CA) 125 202.5 SC
Palivizumab Synagis MedImmune (Gaithersburg, MD) 100 50, 100 IM
Panitumumab Vectibix Amgen (Thousand Oaks, CA) 20 100, 200, 400 IV
Ranibizumab Lucentis Genentech (South San Francisco, CA) 10 2 II
Rinolacept Arcalyst Regeneron (Eastview, NY) 80 220 SC
Tocilizumab Actemra Genentech (South San Francisco, CA) 20 80, 200, 400 IV
Tositumomab Bexxar GlaxoSmithKline (Seattle,WA) 14 35, 225 IV
Trastuzumab Herceptin Genentech (South San Francisco, CA) 21 440 IV
Ustekinumab Stelara Janssen Biotech (Horsham, PA) 90 45, 90 SC
SC for subcutaneous injection; IV for intravenous infusion; II for intravitreal injection; IM for intramuscular injection.
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conditions and processing time during UF/DF. Three different
frameworks for generating manufacturability indices are demon-
strated in order to address different user priorities. The three
frameworks centered on derivation of either quantiﬁed overlay
regions or temporal operating windows or temporal multi-criteria
weighted scores. The work demonstrates that these frameworks
provide a systematic and holistic approach to leverage formulation
screening data so as to predict manufacturability. It is envisaged that
advances in high-throughput assays and automation may allow such
formulation studies to be carried out earlier in the development cycle,
potentially across multiple candidates in the drug discovery phase.
Hence the approaches presented in this work have also potential
utility to be incorporated not only into early formulation studies but
also into molecular/developability assessment exercises so as to de-
risk technical development.
This paper is organized as follows: ﬁrst, the methods applied in
the case study including CART decision tree and regression analysis
are brieﬂy introduced. Second, the published experimental DoE
data used in the case study is summarized and the practical
problems to be solved by the case study are described. In the Section
Decision Tree Analysis Results, the key factors impacting viscosity
and thermostability are derived using CART decision trees. In the
Section Manufacturability Index Results, three proposed method-
ologies are analyzed for the derivation of manufacturability indices.
These indices consider the impact of the protein concentration-time
proﬁles on manufacturability, whilst accounting for the expected
ﬂux decay behavior during UF/DF. Multivariate regression and
calculus techniques are used to transform experimental data into a
set of viscosity and thermostability stress maps as a function of the
formulation conditions and the time proﬁles during UF/DF and
ﬁnally to derive the indices.
Methodology
Classification and Regression Tree (CART)
Classiﬁcation and regression tree (CART) is a nonparametric
procedure to construct prediction models and to establish
splitting rules (Breiman et al., 1984; Grajski et al., 1986). CART
divides the data into homogenous subsets using binary recursive
partitions. The most discriminative variable is ﬁrst selected as the
root node to partition the data set into branch nodes. The root
nodes and branch nodes in this study represent critical
formulation parameters affecting protein solution viscosity and
thermostability. The partitioning is repeated until the nodes are
homogenous enough to be terminal nodes, which are called
leaves. The terminal nodes represent critical ranges for the output
metric of interest. So in a tree structure, each leaf represents a
class label and each branch represents the splitting rules that lead
to those class labels.
CART is able to convert large complex datasets into easy-to-
understand and yet information-rich graphical displays with
minimal requirements for data preparation and robust performance
on large datasets. Furthermore, CART has been demonstrated for
biomanufacturing facility ﬁt analysis to explore the impact of these
process ﬂuctuations on product mass loss and reveal the root causes
of bioprocess bottlenecks (Yang et al., 2014). In the current work,
CART was introduced to identify the major factors affecting
viscosity and thermostability.
Regression Analysis
Regression analysis is a statistical modeling approach for
estimating the relationships among variables and is widely used
for prediction and forecasting. Regression attempts to model the
relationship between a set of input variables (independent
variables) and a set of output variables (dependent variables).
In this work, polynomial regression has been used to analyze the
DoE data and derive polynomial equations describing the
relationship between viscosity and formulation factors. These
polynomial equations have been used for manufacturability index
calculations at a later stage. Furthermore, according to the impact
factor analysis in the literature (He et al., 2011c), polynomial
models can ﬁt the DoE data well.
Case Study Description
Formulation DoE Datasets
The datasets used in this work have been published by He et al.
(2011c). The datasets describe the high-throughput measurements
of thermostability and viscosity for an IgG2 mAb sample assessed
using differential scanning ﬂuorimetry (DSF) and dynamic light
scattering (DLS) methods respectively (Shukla et al., 2007). He et al.
(2011c) obtained the data via a full factorial design of experiments
(DoE) with four predictor variables, including two continuous
variables (pH and formulation concentration) and two categorical
variables (presence of ions and excipient). Table II describes the
summary of DoE predictor variables.
Problem Domain
For high concentration mAb manufacture, the key challenge is the
ﬁnal UF/DF step due to high viscosity. A typical mAb concentration
entering the ﬁnal UF/DF step is 5–10 g/L (Pollock et al., 2013).
However, at the ﬁnal UF/DF step, the mAb needs to be concentrated
to the ﬁnal desired concentrations which usually exceeds 100 g/L
(Harris et al., 2004). Furthermore, in order to reduce the mass loss
caused by hold-up volumes (e.g., in piping) of TFF skids, Rao and
Gefroh (2012) reported that some manufacturers have introduced
extra overconcentration and ﬂush sub-steps in the ﬁnal UF/DF step
so as to recover as much as possible of the product held outside of
the retentate tank in large-scale skids. That means in high
Table II. Summary of DoE predictor variables.
DoE predictors Variables
pH 5.0 5.5 6.0
Formulation concentration (g/L) 89 119 149
Ion N/A Ca2þ Mg2þ
Excipient N/A Sucrose Proline
CaCl2 and MgCl2 were included at 50mM. Final concentration of sucrose or
proline was 200mM.
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concentration protein manufacturing processes, the product
concentration during the ﬁnal UF/DF step is even higher than
the target concentration. This poses a challenge because of the high
viscosity and propensity to aggregate at the higher concentrations.
Consequently, the product viscosity and thermostability levels need
to be within acceptable limits beyond the target product
concentration to be able to cope with higher stresses experienced
during the UF/DF step. Hence it is important to be able to identify
the optimal formulation conditions that reduce the solution
viscosity and enhance the product thermostability during the ﬁnal
UF/DF step so as to avoid manufacturing obstacles.
In this case study, the required ﬁnal product concentration is
100 g/L. The concentration after entering the UF/DF step is 5 g/L.
The overconcentration ratio in the ﬁnal UF/DF step is 1.5 which
means the product concentration is 150 g/L after the overconcen-
tration step. The inﬂuence of different formulation conditions on
solution viscosity and thermostability has been explored by high-
throughput DoE experiment as described in the Section Formula-
tion DoE Datasets. The aim of this work is to rank different
formulation designs according to their potential UF/DF manufac-
turability and to choose the optimal formulation conditions that
minimize the potential for viscosity issues while meeting the
thermostability requirement.
Decision Tree Analysis Results
CART Tree for Identification of Key Factors Influencing
Viscosity
As described in Section Formulation DoE Datasets, the published
viscosity DoE dataset has 80 data records. Each data record
represents one formulation design with a combination of four
variables: pH, formulation concentration, presence of ions, and
excipient. Each data record in the DoE dataset was assigned a
class label of either high viscosity (6 cP) or low viscosity (<6
cP). This enabled the supervisory learning method used by the
decision tree classiﬁcation to identify key contributory factors
leading to each outcome. The threshold value used for high
viscosity was the set to be the same as that used in the original
data source (He et al., 2011c). Although the critical viscosity value
(6 cP) may be considered low, recent studies have demonstrated
that the viscosity of mAb solutions can experience sharp
exponential increases with mAb concentrations, particularly
above 100 g/L and above viscosities of 5–10 cP (Yadav et al.,
2010b). Hence the threshold value used in the analysis could be
considered industrially relevant but should not be seen as
deﬁnitive. It was selected with the primary aim of demonstrating
the application of the proposed methodologies to transform
formulation datasets into predictive manufacturability assess-
ments and enable comparisons with previous work using the
same data source (He et al., 2011c).
In Figure 1(a), the CART tree for the viscosity dataset reveals that
the most critical factors inﬂuencing the solution viscosity are
formulation concentration followed by presence of ions and ﬁnally
presence of excipients. The pH values have less impact on viscosity
in this particular dataset. In order to clearly display the relationship
between the viscosity distribution and key factors based on the
decision tree prediction model, plots of formulation concentration
versus presence of ions under the presence of different excipients
were generated in Figure 1(b). Several conclusions can be drawn
from examination of Figures 1(a) and (b):
 Viscosity is highly related to formulation concentration rather
than other factors. When the formulation concentration is low
(89 g/L), low viscosity (<6 cP) is expected irrespective of the
other factors. On the other hand, when the formulation
concentration is high (149 g/L), viscosity will be high (6 cP)
irrespective of the other factors. This observation reinforces
literature reports that protein solution viscosity increases rapidly
with increasing concentration due to the reversible self-
association and weak intermolecular interactions between
protein molecules at high concentration (Liu et al., 2005, Yadav
et al., 2010a, Yadav et al., 2010b).
 For a medium formulation concentration of 119 g/L, the
presence of Ca2+ and Mg2+ ions can reduce viscosity to lower
than 6 cP in the absence of sucrose excipient. The impact of ions
can be explained by the interaction between charged ions and
charged amino acid side chains on the protein surface which
alters protein–protein interactions and decreases the solution
viscosity (He et al., 2010a; Kanai et al., 2008; Liu et al., 2005).
 Compared to proline, the presence of sucrose excipient can lead
to higher viscosity especially at the medium formulation
concentration of 119 g/L. This effect of sucrose on the solution
viscosity has been reported in previous work and has been
explained by the interactions between sugar and protein
molecules in solution (He et al., 2011b; Kanai et al., 2008).
CART Tree for Identification of Key Factors Influencing
Thermostability
Similar to the viscosity dataset, according to the values of
hydrophobic exposure temperature (Th), the thermostability dataset
with 80 data records was classiﬁed into one of two groups: stable
(50 C) and unstable (<50 C). The low limit of hydrophobic
exposure temperature was set at 50 C according to the literature
source (He et al., 2011c). The CART tree is shown in Figure 1(c). The
tree shows that pH followed by presence of ions and then presence of
excipients are critical formulation variables affecting thermostability,
while formulation concentration was not found to be as signiﬁcant as
the other variables. This result is corroborated by the statistical
analysis results of the literature source (He et al., 2011c). Plots of pH
values against presence of ions under different excipients are
generated in Figure 1(d). Similar conclusions can be drawn from
observations of Figures 1(c) and (d):
 pH value has the most effect on thermostability. High pH values
(5.5 and 6.0) are more likely to have high hydrophobic exposure
temperature and vice versa. When pH is 5.0, low Th (<50 C) is
expected irrespective of the other factors which means the
proteins are unstable. Effects of pH on mAb stability have been
reported in previous work (Vermeer and Norde, 2000) and it
could be explained by the low temperatures of unfolding that
occur at low pHs (Vermeer et al., 2000).
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 When pH is 5.5, the presence of Ca2+ can reduce the protein
thermostability at high pH levels (5.5 and 6.0) under the
condition without any excipient. However, when pH is 6.0, the
presence of excipient, either proline or sucrose, will compensate
the effect of Ca2+ and lead to high thermostability again. The
same observations about the addition of ions decreasing protein
thermostability and the effect of Ca2+ being more signiﬁcant
than the effect of Mg2+ have been reported in He et al. (2011c).
This section has shown that the CART tree method has correctly
identiﬁed the main inﬂuences on mAb viscosity and thermostabil-
ity, and therefore acts as a suitable input for the work on
manufacturability indices, as discussed below.
Manufacturability Index Results
In this work, three different multi-criteria frameworks are proposed
and implemented to derive manufacturability indices: “quantiﬁed
overlay region”, “temporal operating window”, and “temporal
multi-criteria weighted score” framework. The manufacturability
index is a set of numbers which can indicate the ease of
manufacture during the ﬁnal UF/DF step for each formulation
candidate.
Manufacturability Index Derived Using the Quantified
Overlay Region Framework
Step 1: Generation of Stress Maps
A stress map is a contour plot to explore how the performance or
product quality (e.g., viscosity, thermostability in this work)
changes with key process parameters (e.g., product concentration,
pH). As described in the Section Methodology, there are two
categorical variables: presence of ions and excipient. According to
the combinations of ion and excipient, both viscosity and
thermostability datasets were divided into nine sub-datasets such
as no ion with no excipient or Ca2+ ion with sucrose excipient. Nine
Figure 1. Data mining results for formulation conditions driving viscosity and thermostability. a) CART tree for viscosity factors analysis. Rectangular nodes are branch nodes
(e.g., concentration, pH) which represent the formulation factors leading to split. Values on branches are the threshold levels of the split points for the corresponding split conditions.
Circular nodes are leaves representing subsets with different class labels for viscosity (solution viscosity is higher or not than 6 cP). b) Impact of different combinations of
formulation factors on viscosity with sucrose excipient or proline/no excipient. The blue area represents formulations with low solution viscosity (<6 cP), and the red area
represents formulations with high solution viscosity (6 cP). c) CART tree for thermostability analysis. Circular nodes are leaves representing subsets with different class labels for
thermostability (Th is higher or not than 50
C). b) Impact of different combinations of formulation factors on thermostability, with no excipient and with excipient (sucrose or proline
excipient). The red area represents formulations unstable at 50

C (Th< 50
C), blue area represents formulations stable at 50 C (Th 50 C).
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polynomial models in the form shown in Equations (1) and (2) that
describe viscosity and thermostability as a function of pH and
protein concentration were built by polynomial regression for all
formulation designs.
V x; yð Þ ¼ a00 þ a10xþ a01yþ a11xyþ a20x2 þ a02y2 ð1Þ
T x; yð Þ ¼ a00 þ a10xþ a01y ð2Þ
where V(x,y) represents the viscosity values, T(x,y) represents the
thermostability values, x is protein concentration, and y is pH value.
For the formulation of no ion with no excipient, the viscosity stress
map and thermostability stress map are shown in Figure 2(a).
For each formulation design, the viscosity stress map indicates
the prediction values of viscosity (cP) under different pH and
protein concentrations while the thermostability stress map
indicates the prediction values of hydrophobic exposure tempera-
ture (C) under different pH and protein concentrations.
Both viscosity and thermostability stress maps will be used later
to generate manufacturability indices for ranking formulation
designs.
Step 2: Validation of Stress Maps
In order to validate the regression models for viscosity and
thermostability stress map, plots of actual values against the
predicted values from the regression models of viscosity and
thermostability were generated and examined in terms of goodness
of ﬁt (R2). Taking the formulation of no ion with no excipient as an
example as shown in Figure 2(b), the triangles represent actual
values while the dots represent predicted values. For the
formulation of no ion with no excipient, the viscosity regression
model has R2 values of 0.95 indicating that approximately 95% of
the variation in the response could be explained by the model while
the thermostability regression model has R2 values of 0.96. Similar
goodness of ﬁt values (91–97% for viscosity and 85–99% for
thermostability) were observed for the eight other formulation
condition combinations.
Figure 2. Methodology of quantified overlay region framework to generate manufacturability index for formulation of no ion with no excipient. (a) Generate viscosity and
thermostability stress maps as functions of pH and protein concentration. (b) Validate the regression models for viscosity and thermostability stress map. Plots of actual values
against the predicted values from regression models of viscosity and thermostability for formulation of no ion with no excipient. The blue triangles represent actual values while red
dots represent predicted values. (c) Calculate manufacturability index for formulation of no ion with no excipient to meet both viscosity and thermostability requirements. The blue
line is the contour line of viscosity of 6 cP, while the green line is the contour line of thermostability of 50 C. The shaded area is the overlapping window to meet both requirements of
viscosity<6 cP and thermostability>50 C. The manufacturing index (0.35 in this example) is calculated as the ratio of the overlapping window area over the whole stress map area.
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Step 3: Generation of Manufacturability Index by
Quantifying the Overlay Region
Using stress maps, the predicted values for thermostability and
viscosity at a particular pH and protein concentration for different
formulation designs can be assessed. It is also possible to select the
optimal pH and concentration range to meet speciﬁc limits for both
thermostability and viscosity by overlapping the stress maps. If the
critical values for viscosity and thermostability are 6 cP and 50 C,
respectively, Figure 2c shows the overlaid stress map for the
formulation of no ion with no excipient. In Figure 2c, the curved
(blue) contour indicates the critical viscosity value and the area
below this contour is the desired area where viscosity values are
lower than the critical value. The straight diagonal (green) contour
indicates the critical Th value and the area above this line is the
desired area where Th values are higher than critical value. The
shaded area in Figure 2c, indicating the overlaid contour region,
indicates the range of pH and concentrations that meet both
thermostability and viscosity requirements for the formulation of
no ion with no excipient. The manufacturability index based on the
quantiﬁed overlay region framework is deﬁned as the ratio of the
overlay area to the whole stress map area. For example, for the
formulation of no ion with no excipient highlighted in Figure 2c, the
manufacturability index determined by the quantiﬁed overlay
region framework is 0.35.
Selection of Optimal Formulation
The manufacturability indices generated using the quantiﬁed
overlay region framework for all formulation conditions are shown
in Figure 3. The indices were used to rank order the formulation
designs, where a higher index value was considered more desirable
given the wider allowable range of pH and concentration values to
satisfy both thermostability and viscosity requirements. The best
formulation condition was predicted to be no ion with sucrose
followed by no ion with proline and no ion with no excipient. The
worst formulation condition was found to be Ca2+ ions with no
excipient with an index value of zero since there was no overlapping
region of acceptable pH and protein concentration values meeting
Figure 3. Manufacturability indices by quantified overlay region for all formulation conditions. The higher manufacturability index values indicate the higher tolerance
capability to meet both requirements of viscosity<6 cP and thermostability>50 C. The best formulation condition is no ion with sucrose, followed by no ion with proline and no ion
with no excipient. For the formulation of Ca2+ with no excipient, the manufactuability index is 0 since there is no overlapping window for this formulation to meet both requirements.
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both thermostability and viscosity requirements. This framework is
suitable for testing the robustness of formulation designs based on
their overlay region size without consideration of UF/DF process
parameters or a target ﬁnal product concentration. Therefore, it can
be used as the initial evaluation of formulation conditions without a
speciﬁc target product proﬁle.
Previous work has used overlay contour plots to explore the
acceptable range of pH and salt concentration at particular limits
for Th and diffusion interaction parameter values (He et al., 2011a)
and for Th and viscosity values (He et al., 2011c). In this work, the
analysis has been taken a step further by moving from visual
inspection of the overlay regions to determining a numerical
manufacturability index for each formulation combination based
on the size of the overlay region. This provides a rapid methodology
for ranking the different formulation conditions in a systematic
manner.
Manufacturability Index Derived Using the Temporal
Operating Window Framework
Step 1: Operating Window Location Using the
Thermostability Criterion
In this framework, the operating window is deﬁned as the actual
product concentration range and the optimal pH range experienced
during the overconcentration and ﬂush stages of the ﬁnal UF/DF
step. As described in the Section Problem Domain, the product
stream after entering the UF/DF step is at 5 g/L, and during ﬁnal
UF/DF, it is concentrated to 150 g/L at the overconcentration step
and diluted to 100 g/L at the ﬂush step. In this work, only the upper
values of the concentration range typically experienced during the
overconcentration and ﬂush stages (90–150 g/L) are considered
since they have the potential to pose greater viscosity challenges
during manufacture. The pH range is determined by the
thermostability requirement for the ﬁnal product speciﬁcation of
100 g/L. Although thermostability temperatures will not be
experienced during the ﬁnal UF/DF step since the ﬁltration
operations are usually conducted at room temperature, the
tolerance of hydrophobic exposure temperature (Th) may affect
the protein product’s long-term stability during transition and
storage. Therefore, it is meaningful to consider thermostability
when choosing the best formulation conditions in the ﬁnal UF/DF
step as it is the last manufacturing step prior to ﬁll-ﬁnish
operations.
Since the thermostability criterion was set as Th 50 C as
described in the Section CART Tree for Identiﬁcation of Key
Factors Inﬂuencing Viscosity, an operating window has been set
up for each formulation design to identify the optimal pH range
that meets the thermostability requirement. Figure 4(a) illustrates
the identiﬁcation of the operating window for the formulation
condition of no ion with no excipient. In Figure 4(a), the vertical
(white) contour indicates the ﬁnal product concentration of 100 g/
L and the diagonal (red) contour indicates the thermostability
criterion. The intersection of the red and white contours indicates
the pH value for the ﬁnal product speciﬁcation to meet the
thermostability criterion. For example, for the formulation
condition of no ion with no excipient illustrated in Figure 4a,
the pH required is 5.3. Considering that a typical pH control
range is within 0.2 units, the operating window is determined
by the ranges of concentration and pH that are 90–150 g/L and
5.1–5.5, respectively, as indicated by the rectangular overlay
region in Figure 4(a).
Step 2: Processing Time Exposed to Different Viscosity
Levels in Final UF/DF
In the ﬁnal UF/DF step, the concentration of the product stream,
and hence its viscosity, are dynamically changing over time.
Furthermore, the ﬂux through the membrane can be signiﬁcantly
lowered by membrane pore blockage and protein fouling that
occurs as the concentration increases. In order to capture the
information about the time exposed to different viscosity levels
during UF/DF, the mathematical model for the ﬁltrate ﬂux
proposed by Ho and Zydney (2000) was adapted and incorporated
as Equation (3). In this work, the model has been adapted to not
only capture the decreasing ﬂux rate due to membrane fouling
but also account for the impact of changing protein concentration
over time on ﬂux behavior:
Q tð Þ ¼ Q0 exp 
/ DPC tð Þ
mRm
t
 
þ Rm
Rm þ Rp 1 exp 
/ DPC tð Þ
mRm
t
  
ð3Þ
where Q0is the initial volumetric ﬂow rate through the clean
membrane, m is the solution viscosity, DP is the transmembrane
pressure, Rm is the clean membrane resistance, t is processing time,
and / is a pore blockage parameter which is equal to the
membrane area blocked per unit mass of protein convected to the
membrane surface.
The resistance of the protein deposit over a particular region of
the membrane Rp is evaluated by Equation (4):
Rp ¼ Rm þ Rp0
 	
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1þ 2
0
f R
0DPCb
m Rm þ Rp0
 	2 t
vuut  Rm ð4Þ
where Rp0 is the initial resistance of the protein deposit, R0 is the
speciﬁc protein layer resistance, and f 0 is the fraction of the proteins
that contribute to the growth of the deposit.
The protein concentration during UF/DF, C(t) as a function of
ﬁltration ﬂux and time is calculated by Equation (5):
C tð Þ ¼ C0V0
V0 
Xn
t¼0Q tð ÞDt
ð5Þ
where V0 is the initial protein stream volume, C0 is the initial
protein concentration, Dt is the time interval between C(t) and C
(tþ 1).
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The values of parameters for the ﬂux decay model in this work
are listed in Table III. These were derived from the literature (Ho
and Zydney, 2000) and discussion with industry experts.
Using this model, the variation of protein concentration with
processing time during the overconcentration and ﬂush stages of
the UF/DF step has been captured, as illustrated in Figure 4(b).
Step 3: Generation of Manufacturability Scores
With the model of processing time exposed to different viscosity
levels in ﬁnal UF/DF, the viscosity stress maps can be transformed
as a function of pH and processing time. Figure 4(c) shows the
transformed viscosity stress map for the formulation condition of
no ion with no excipient. The operating window for the formulation
condition of no ion with no excipient is determined by the ranges of
processing time and pH which are 104–191min and 5.1–5.5,
respectively.
The average of viscosity values within the temporal operating
window, termed the viscosity score, is calculated by Equation (6).
Viscosity score ¼
Xmax pH
min pH
Xmaxt
mint
m pH; tð Þ
NtNpH
ð6Þ
Table III. The parameters for flux decay model used in the work.
Parameters Q0 / DP C0 V0 m Rm f0R0 Rp0
Value 5000 0.33 5 105 20 1050 0.001 7.5 1011 16 1011 3 1010
Unit L/h m2/kg Pas g/L L kg/m/s m1 m/kg m1
Figure 4. Methodology of temporal operating window framework to generate manufactuability index for formulation of no ion with no excipient. (a) Locate window of operation
using the thermostability criterion. In the viscosity stress map for formulation of no ion with no excipient, the red line shows thermostability criterion Th¼ 50 C, while the white line
shows the final product concentration of 100 g/L. The intersection of the red and white lines represents the pH for final product to meet Th¼ 50 C, which is 5.3. The operating range
of pH is set to0.2, so the pH range of window of operation is 5.1–5.5. (b) Capture the time profile of product stream during overconcentration stage and flush stage in the final UF/DF
step captured by the flux decay model. (c) Calculate the viscosity score as a pH and time weighted viscosity score. The viscosity score of formulation of no ion with no excipient is
5.2 cP. (d) Calculate manufacturability index as standard the viscosity scores into [0, 1]. The manufacturing index of formulation of no ion with no excipient is 0.5.
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where m pH; tð Þ is the viscosity regression model considering
concentration-time proﬁle, which is a function of pH value and
processing time t. Nt and NpH are the intervals of processing time t
and pH, respectively, within the temporal operating window. The
score indicates the average viscosity value of the product stream
during the UF/DF step taking into account the operating range
of pH and the time proﬁles of concentration. For example, for the
formulation condition of no ion with no excipient, the viscosity score
is 5.2 cP.
Step 4: Generation of Manufacturability Indices
The viscosity scores for all formulation conditions were
standardized to [0, 1] so as to generate manufacturability indices
using Equation (7).
Manufacturability index ¼ viscosity score worst score
best score worst score : ð7Þ
The reason for the transformation of viscosity scores is to obtain
a set of uniform manufacturability indices to represent the ease of
manufacture with the higher value the more desirable. The
manufacturability index for the formulation condition of no ion
with no excipient is 0.5.
Selection of Optimal Formulation
Manufacturability indices were generated for all formulation
designs as shown in Figure 5. Each set of formulation conditions
can be ranked according to their manufacturability indices where a
higher index value indicates a more desirable outcome. From
Figure 5, it can be seen that Ca2+ ions with proline excipient is the
optimal formulation design with the highest manufacturability
index, 1. Similarly, to the quantiﬁed overlay region results, there is
no operating window for the formulation of Ca2+ ions with no
excipient since the pH required for the ﬁnal product to meet the
thermostability criterion is 6.4 which is outside the experimental
range of the dataset (5–6). Furthermore, if the critical acceptable
viscosity value for the ﬁnal UF/DF step is 6 cP (which translates to a
manufacturability index of 0.14), three formulation designs would
not be feasible: Ca2+ ions with no excipient, Ca2+ ions with sucrose
excipient, and Mg2+ ions with sucrose excipient.
In this strategy, the rank order of formulation designs based on the
temporal operating window framework is different to that from the
quantiﬁed overlay region one. The reason for the difference is due to
the additional consideration of the thermostability criterion. The
position of the window is determined by the pH value for each
formulation design to meet the thermostability criterion (50 C). For
example, the formulation of no ion with sucrose generally leads to the
Figure 5. Manufacturability indices by temporal operating window for all formulation conditions. The index indicates the average viscosity value of the product stream during
the UF/DF step taking into account the time profiles of pH and concentration. Each set of formulation conditions can be ranked according to their manufacturability indices where a
higher index value indicates a more desirable outcome. The best formulation is Ca2+ with proline, followed by no ion with proline and no ion with sucrose. The three formulations in
the red window are the worst three formulation conditions of all.
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highest viscosity in all formulation designs. However, since sucrose
can enhance the protein thermostability so that the pH value to meet
thermostability criteria is the lowest, the formulation of no ion with
sucrose is the second best design from the temporal operating
window perspective.
Compared to the quantiﬁed overlay region framework in the
Section Manufacturability Index Derived Using the Quantiﬁed
Overlay Region Framework, this framework can rank and select
formulation designs considering the process parameters (such as
ﬂux rate, membrane fouling, and overconcentration ratio) and time
proﬁles during the ﬁnal UF/DF step. This framework requires
speciﬁcation of the ﬁnal product concentration.
Manufacturability Index Derived Using the Temporal
Multi-Criteria Weighted Score Framework
In this section, thermostability was considered indicative of
aggregation propensity where a high thermostability value and
hence high-protein conformational stability was taken as an
indicator of low aggregation propensity (Goldberg et al., 2011).
Step 1: Standardizing Viscosity and Thermostability Values
Scores for viscosity and aggregation have been derived by
standardizing the real values of viscosity and thermostability to
[0, 1] using the same method as Equation (7) in order to eliminate
the bias caused by different value ranges of aggregation and viscosity.
If there are any extreme values or outliers in the viscosity and
aggregation datasets, standard data processing methods should be
used to remove outliers before standardizing. Then, similar to the
Section Manufacturability Index Derived Using the Quantiﬁed
Overlay Region Framework, stress maps that describe the scores for
viscosity and aggregation as a function of pH and protein
concentrationwere built by polynomial regression for all formulation
designs. Using the same model of processing time exposed to
different viscosity levels in the ﬁnal UF/DF described in the Section
Manufacturability Index Derived Using the Temporal Operating
Window Framework, the stress maps for viscosity and aggregation
can be transformed as a function of pH and processing time. Figure 6
(a) shows the standardized viscosity and aggregation stress maps for
the formulation condition of no ion with no excipient.
Step 2: Generate Multi-Criteria Weighted
Manufacturability Stress Maps and Scores
The weighted sum model, a popular multi-criteria decision analysis
method, was used to combine scores of aggregation and viscosity.
Multi-criteria manufacturability, deﬁned as the weighted sum of
viscosity and aggregation scores, is a function of pH and processing
time. Figure 6(b) shows the manufacturability stress map for the
formulation condition of no ion with no excipient when aggregation
and viscosity are equally weighted. Different colors indicate different
manufacturability levels. From blue to red, manufacturability is from
easy to hard.
A set of temporal multi-criteria weighted manufacturability
scores were calculated by averaging the manufacturability scores
over the UF/DF processing time for each pH value (Equation [8]).
The manufacturability index value is selected as the maximum
temporal multi-criteira weighted score and hence the
corresponding pH that maximized manufactruability is considered
the optimal pH value.
Manufacturability score ¼
Xn
t¼i
ðaVt þ bAtÞ n ið Þ ð8Þ
where Vt is viscosity score at time t, A is aggregation score at time t,
a and b are weights assigned to the viscosity and aggregation scores
respectively to reﬂect user priorities.
Step 3: Select Manufacturability Index from Multi-Criteria
Weighted Manufacturability Scores
Figure 6(c) shows manufacturability stress maps by multi-criteria
decisions for the formulation condition of no ion with no excipient.
The weights of viscosity and aggregation represent different user
preference scenarios with different weights given to viscosity and
aggregation: equally weighted (a¼ 0.5, b¼ 0.5), or viscosity
considered more important than aggregation (a¼ 0.8, b¼ 0.2), or
aggregation considered more important than viscosity (a¼ 0.2,
b¼ 0.8). For example, when producing stable products, users may
pay more attention to viscosity, therefore, in this case, the viscosity
would have a higher weighting than aggregation. In contrast, when
producing thermosensitive products, users may pay more attention
to aggregation, therefore, the aggregation’sweighting would be higher
than viscosity. The red lines in Figure 6(c) indicate the optimal pH
values that result in the maximum average manufacturability score
for each of theweight scenarios. Comparing the three plots in Figure 6
(c), it can be seen that the optimal pH value changeswith the weights.
When the weights of viscosity and aggregation are 0.2 and 0.8,
respectively, the optimal pH is 6 and themaximummanufacturability
is 0.76; when the weights are 0.5 and 0.5, the optimal pH is 5.9 and the
maximummanufacturablity is 0.73; when theweights are 0.8 and 0.2,
the optimal pH is 5.4 and the maximum manufacturability is 0.79.
The trend suggests that when viscosity has a higher weighting, the
optimal pH value is at the lower end of the range and conversely if
aggregation has a higher weighting then the optial pH value is toward
the upper end of the range.
Selection of Optimal Formulation
Figure 7 compares all formulation conditions according to their
manufacturability indices using the multi-criteria weighted score
framework with different weights on viscosity and aggregation.
Each set of formulation conditions has been ranked from 1 to 9
when the weights on viscosity and aggregation are 0.2 and 0.8, 0.5
and 0.5, 0.8 and 0.2, respectively. Different colors indicate different
rank orders where 1 is the best formulation condition with the
maximum manufacturability index value and 9 is the worst.
Although the ranking of formulation conditions is changing with
the weightings, several generic conclusions can be drawn:
 For all the three sets of weights on viscosity and aggregation, the
best formulation condition is always no ion with sucrose. This
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can be attributed to the fact that sucrose improves the
aggregation score dramatically whilst only lowering viscosity
score slightly. As a result, the maximum weighted sum of
viscosity and aggregation is always in the formulation condition
of no ion with sucrose.
 The worst formulation condition in all three weighting scenarios
is always Ca2+ with no excipient. Although Ca2+ can beneﬁt the
viscosity score, its negative effect on aggregation is much more
signiﬁcant so that the lowest weighted sum of viscosity and
aggregation is always in this formulation.
 When the weights of viscosity and aggregation are 0.2 and 0.8,
the best formulation condition is no ion with sucrose followed by
the joint ranking of no ion with no excipient and no ion with
proline. The worst formulation condition is Ca2+ with no
excipient, followed byMg2+ with no excipient and then both Ca2+
with sucrose and Ca2+ with proline. This result reveals that when
the weight of aggregation is higher than viscosity, the optimal
formulation conditions favor no ions or the presence of
excipient. This result also reinforces previously reported
observations that excipients can increase thermostability whilst
ions can decrease thermostability (He et al., 2010b). This result
is consistent with the quantiﬁed overlay region result in the
Section Manufacturability Index Derived Using the Quantiﬁed
Overlay Region Framework.
 When the weights of viscosity and thermostability are 0.8 and
0.2, the best formulation condition is no ion with sucrose
followed by the equally ranked no ion with proline and Ca2+ with
proline. The worst condition is Ca2+ with no excipient, followed
by Ca2+ with sucrose, Mg2+ with no excipient and Mg2+ with
sucrose. This result reveals that when the weight of viscosity is
higher, the optimal formulation conditions favour the presence
of proline. This observation is corroborated by studies indicating
Figure 6. Methodology of temporal multi-criteria weighted score framework to generate manufacturability index for formulation of no ion with no excipient. (a) Step 1:
Standardize the real values of both viscosity and thermostability into [0, 1] to derive scores for viscosity and aggregation. Then, polynomial regression combined with the flux decay
model was applied to the scores to generate stress maps for viscosity and aggregation as a function of time. In this framework, thermostability acts as an indicator of aggregation.
(b) Step 2: Combine viscosity and aggregation scores using weighted sum method (WSM). Manufacturability, defined as weighted sum of viscosity and aggregation scores, is a
function of pH and processing time. Different colors indicate different manufacturability levels. From blue to red, manufacturability is from easy to hard. Average manufacturability
value for each pH calculated and the pH with the maximum average manufacturability value is the optimal pH value. When the weights for viscosity and aggregation are 0.5 and 0.5
separately, the optimal pH value for formulation no ion with no excipient is 5.9 and the maximum manufacturability is 0.73. (c) Step 3: Derive a multi-criteria weighted
manufacturability index for UF/DF averaged over time at the optimal pH value. The red lines indicate the optimal pH values for maximum manufacturability through the final UF/DF
step. The optimal pH value changeswith theweights.When a¼ 0.5, b¼ 0.5, the optimal pH is 5.9 and themaximummanufacturablity is 0.73; when a¼ 0.2, b¼ 0.8, the optimal pH is 6.0
and the maximum manufacturability is 0.76; when a¼ 0.8, b¼ 0.2, the optimal pH is 5.4 and the maximum manufacturability is 0.79.
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that proline effectively inhibits protein aggregation due to the
formation of an ordered, amphipathic supramolecular assembly
(Kumar et al., 1998). This result is consistent with the temporal
operating window result in the Section Manufacturability Index
Derived Using the Temporal Operating Window Framework.
 When viscosity and aggregation are equally weighted, the
formulation conditions of Mg2+ with sucrose and no ion with
sucrose are tied in terms of attractiveness followed by Mg2+ with
proline. The worst formulation condition is Ca2+ with no
excipient, followed by Mg2+ with no excipient and Ca2+ with
sucrose equally. This result reveals that when the weights of
viscosity and aggregation are equal, there will be more
complicated trade-offs between the presence of ions and
excipients so that the optimal formulation conditions favour the
presence of Mg2+ with excipients.
Conclusion
It is important to be able to select candidates early on based on both
the ideal formulation for clinical efﬁcacy and uptake but also for
manufacturability. This work presents the concept of manufactur-
ability indices as early predictors to select the optimal formulation
designs for selected candidates. Three quantitative index-generation
frameworks (quantiﬁed overlay region, temporal operating window,
and temporal multi-criteria weighted score) have been proposed and
demonstrated in this work. The three frameworks analyzed the same
DoE datasets from static, temporal, and weighted multi-criteria
perspectives, respectively, to generate manufacturability indices.
Each framework could rank the formulation designs and choose the
optimal formulation of buffer conditions with the best potential
manufacturability for the ﬁnal UF/DF step in high-concentratedmAb
manufacturing processes. Although the rank order is different, all
three frameworks have their own advantages and applications.
The advantage of the quantiﬁed overlay region framework is its
simplicity and directness. Since this framework does not relate to
speciﬁc unit operation steps and ﬁnal product concentration it can
be used as the initial evaluation of formulation conditions. The
advantage of the temporal operating window framework is that it
can be used as an advanced predictor for a particular product and
speciﬁc UF/DF processing parameters. The advantage of the multi-
criteria decision framework is its ﬂexibility. The weightings of
viscosity and stability are adjustable so as to satisfy different
manufacturing requirements and user priorities. This framework
also considers the process constraints, time proﬁles during the ﬁnal
UF/DF step and the ﬁnal product concentration. This framework
can be extended to account for optimal manufacturing for
multiproduct facilities.
Another contribution of this work is introducing the CART
decision tree method to explore the inﬂuence of different
formulation conditions on the solution viscosity and thermostabil-
ity and to identify the critical factors for both properties. The results
of decision tree analysis are meaningful for future high-throughput
experiment design and formulation improvement.
This work has laid the foundation for quantitative methodologies
to derive manufacturability indices from biophysical datasets. It has
demonstrated the utility of these indices for formulation screening
studies and their capability to rank order formulation conditions
considering viscosity and thermostability or aggregation propensity
whilst identifying problematic formulations early on. The
development of high throughput assays for measuring such
attributes may also mean that similar stress datasets could in future
be created for multiple candidates prior to entering the development
cycle. Hence the frameworks proposed in this paper could in future
be used during molecular/developability assessments (Lorenz et al.,
2014, Sharma and Kelley, 2015) carried out during the molecule
discovery phase and contribute to candidate selection as well as
formulation design. The measurements of manufacturability are of
course not restricted to viscosity and thermostability; they could
include other biophysical properties such as hydrophobicity and
solubility, quality attributes such as degradation and charge variant
Figure 7. Manufacturability indices by temporal multi-criteria weighted score framework for all formulation conditions. Comparison of all formulation conditions according to
their manufacturability indices using multi-criteria decisions with different weights on viscosity and aggregation. Each set of formulation conditions has been ranked when the
weights on viscosity and aggregation are 0.2 and 0.8, 0.5 and 0.5, 0.8 and 0.2, respectively. Different colors indicate different ranking orders where 1 is the best formulation condition
with maximum manufacturability index value and 9 is the worst.
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levels as well as productivity measurements. Future work will
examine how best to integrate these additional datasets into an
overall manufacturability index that can be considered during
developability assessments so as to help de-risk, streamline and
accelerate biopharmaceutical development.
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